LEVORA 0.15/30-21 Drug Patent Profile
When do Levora 0.15/30-21 patents expire, and when can generic versions of Levora 0.15/30-21 launch?
Levora 0.15/30-21 is a drug marketed by Watson Labs and is included in one NDA.
The generic ingredient in LEVORA 0.15/30-21 is ethinyl estradiol; levonorgestrel. There is one drug master file entry for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LEVORA 0.15/30-21?
- What are the global sales for LEVORA 0.15/30-21?
- What is Average Wholesale Price for LEVORA 0.15/30-21?
Summary for LEVORA 0.15/30-21
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 9 |
| Clinical Trials: | 5 |
| Patent Applications: | 692 |
| DailyMed Link: | LEVORA 0.15/30-21 at DailyMed |
Recent Clinical Trials for LEVORA 0.15/30-21
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AbbVie | Phase 1 |
| Intarcia Therapeutics | Phase 1 |
| University of California, Davis | Phase 4 |
US Patents and Regulatory Information for LEVORA 0.15/30-21
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs | LEVORA 0.15/30-21 | ethinyl estradiol; levonorgestrel | TABLET;ORAL-21 | 073592-001 | Dec 13, 1993 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
LEVORA 0.15/30-21 Market Dynamics, Patent Status, and Financial Trajectory
LEVORA 0.15/30-21 is a combined oral contraceptive containing levonorgestrel 0.15 mg and ethinyl estradiol 0.03 mg. Its commercial position is determined by generic-market economics, not patent exclusivity. The active-ingredient combination has been available for decades, and competing products include Portia-28, Kurvelo, Altavera, Chateal, Lillow, Falmina, and other levonorgestrel/ethinyl estradiol products.
Product-level revenue for LEVORA is not separately disclosed in public filings. The financial trajectory is therefore best assessed through prescription volume, generic pricing, manufacturer participation, payer coverage, and the product’s regulatory and distribution status.
What is LEVORA 0.15/30-21?
LEVORA 0.15/30-21 is a 21-day combined hormonal contraceptive formulation.
| Attribute | Product information |
|---|---|
| Active ingredients | Levonorgestrel 0.15 mg and ethinyl estradiol 0.03 mg |
| Drug class | Combined oral contraceptive |
| Dosage form | Oral tablet |
| Standard regimen | 21 hormone-containing tablets, followed by a hormone-free interval |
| Therapeutic use | Prevention of pregnancy |
| Regulatory category | Prescription drug |
| Reference-product status | Older branded/generic oral contraceptive product |
| Principal competitive products | Portia-28, Kurvelo, Altavera, Chateal, Lillow, Falmina |
| Primary market | United States |
| Commercial model | Generic prescription distribution through pharmacies, wholesalers, and health plans |
LEVORA is pharmacologically comparable to other levonorgestrel/ethinyl estradiol 0.15 mg/0.03 mg products when the dosage regimen and labeling are equivalent. FDA labeling identifies the same core risks associated with combined hormonal contraceptives, including thromboembolic events, cardiovascular risk in smokers, and contraindications involving migraine with aura, uncontrolled hypertension, and prior thrombotic disease. [1]
What is the FDA regulatory status of LEVORA?
LEVORA’s commercial status depends on the specific National Drug Code and manufacturer because the name has been used across product configurations and corporate ownership changes.
The FDA’s Drugs@FDA and Orange Book databases are the principal sources for determining whether a specific LEVORA listing remains approved, marketed, discontinued, or replaced by an equivalent product. FDA records distinguish between an approved product that is not currently marketed and an application that has been withdrawn or discontinued. [2]
The product has no meaningful regulatory exclusivity remaining. Combined oral contraceptives containing levonorgestrel and ethinyl estradiol entered the market long before the modern generic-drug framework matured. Any current LEVORA listing competes primarily through generic substitution and channel access.
FDA regulatory milestones
| Regulatory issue | Commercial implication |
|---|---|
| Original approval of levonorgestrel/ethinyl estradiol contraceptives | Historical approval pathway; no remaining new-drug exclusivity |
| Generic approvals | Multiple ANDA products create direct substitution pressure |
| 21-day packaging | Competes with 28-day packs and equivalent 21-active-tablet regimens |
| Labeling | Safety profile is broadly comparable across equivalent products |
| Product status | Must be evaluated by NDC and manufacturer |
| Current exclusivity | No commercially relevant exclusivity identified |
What patents protect LEVORA 0.15/30-21?
No commercially important patent estate is associated with the basic LEVORA 0.15/30-21 formulation.
The active ingredients, levonorgestrel and ethinyl estradiol, are established compounds. Composition-of-matter patents for these ingredients expired many years ago. The basic tablet combination also lacks the type of formulation complexity that can support a durable modern patent franchise.
| Patent category | Status for LEVORA |
|---|---|
| Levonorgestrel composition patent | Expired |
| Ethinyl estradiol composition patent | Expired |
| Combination-product patent | No significant active exclusivity identified |
| 21-tablet regimen patent | No meaningful market barrier identified |
| Method-of-use patent | No commercially relevant exclusivity identified |
| Manufacturing patent | No product-specific barrier evident from the public record |
| Orange Book-listed patent estate | No material patent protection identified |
The relevant intellectual-property risk is therefore low. A generic competitor would not ordinarily need to design around a meaningful LEVORA patent. The main legal questions concern product-specific approval status, labeling, trademarks, manufacturing compliance, and any private commercial agreement rather than patent validity.
What is the Orange Book status of LEVORA?
The Orange Book is organized around FDA application numbers, active ingredients, dosage forms, strengths, and listed patents. For an older generic contraceptive, the expected result is no active Orange Book patent blocking approval of therapeutically equivalent products.
A specific LEVORA NDC may appear as approved, discontinued, or absent from current marketing depending on the manufacturer and time period reviewed. An NDC-level search is required because product names can persist in pharmacy and payer systems after a particular manufacturer has stopped marketing.
The practical Orange Book conclusion is straightforward: LEVORA does not appear to have an Orange Book patent moat comparable to branded pharmaceutical products with active formulation or method-of-use patents.
When does LEVORA lose exclusivity?
LEVORA’s meaningful market exclusivity has already expired.
The product competes in a mature generic category in which exclusivity is determined by:
- Pharmacy benefit-manager formulary placement.
- Wholesale acquisition and reimbursement economics.
- Manufacturer supply reliability.
- National Drug Code availability.
- Retail pharmacy substitution practices.
- Patient and prescriber familiarity.
- Contracting with Medicaid, commercial insurers, and public-health programs.
Paragraph IV litigation is unlikely to be commercially relevant for the basic LEVORA formulation. A new applicant would not need to challenge a valuable remaining patent estate to enter the levonorgestrel/ethinyl estradiol market. Any Paragraph IV certification would be evaluated against patents listed for the specific reference product, but the absence of meaningful active patents materially reduces litigation risk.
How many products compete with LEVORA?
LEVORA competes with a broad group of therapeutically equivalent or closely comparable oral contraceptives.
Direct equivalents
Common levonorgestrel/ethinyl estradiol 0.15 mg/0.03 mg products include:
- Portia-28
- Kurvelo
- Altavera
- Chateal
- Lillow
- Falmina
- Levora or Levora-28, where still listed or distributed
- Other private-label and manufacturer-specific NDCs
The key difference among products is often packaging rather than pharmacology. A 21-tablet product contains active tablets followed by a hormone-free interval. A 28-tablet product commonly contains 21 active tablets and seven inactive reminder tablets. Payers may treat the products as interchangeable at the therapeutic-class level while maintaining different preferred-product tiers.
Indirect competitors
LEVORA also competes with:
- Norgestrel/ethinyl estradiol products.
- Norethindrone/ethinyl estradiol products.
- Drospirenone/ethinyl estradiol products.
- Progestin-only pills.
- Long-acting reversible contraceptives.
- Vaginal rings, transdermal patches, injections, and intrauterine systems.
- Over-the-counter oral contraceptive options following FDA approval of Opill, a norgestrel progestin-only pill. [3]
The market is segmented by estrogen tolerance, bleeding profile, adherence preferences, contraindications, access, and cost.
What market dynamics affect LEVORA?
LEVORA operates in a high-volume, low-margin pharmaceutical category.
Generic price pressure
Multiple suppliers reduce pricing power. Pharmacy reimbursement is typically based on negotiated generic acquisition costs, maximum allowable cost schedules, or payer-specific reimbursement formulas. Retail prices can vary widely by pharmacy, insurance status, and discount program.
A product with no differentiated delivery technology or protected indication cannot sustain premium pricing unless it has a temporary supply advantage or preferred formulary position.
Contraceptive coverage
Commercial insurance coverage and the Affordable Care Act’s preventive-services framework support utilization of contraceptives, although coverage rules, exemptions, cost-sharing policies, and plan design affect patient access. Medicaid and public-health programs add volume but typically impose substantial reimbursement pressure. [4]
Supply reliability
Supply continuity is strategically important. Oral contraceptive users often require uninterrupted monthly dispensing. A manufacturer with a dependable supply chain can gain pharmacy and payer share even without a clinical advantage.
The principal operational risks include:
- Active pharmaceutical ingredient supply.
- Contract manufacturing capacity.
- Packaging-component shortages.
- FDA manufacturing observations.
- Product recalls.
- Wholesaler allocation.
- NDC discontinuation or substitution.
Brand persistence
LEVORA may retain residual demand among patients and prescribers familiar with the name. That persistence is limited because pharmacists and payers can substitute therapeutically equivalent products, and many contraceptive prescriptions are dispensed under generic names rather than a strong consumer brand.
What is the financial trajectory for LEVORA?
No public company separately reports LEVORA revenue, gross margin, prescription volume, or operating profit. The product’s financial trajectory must therefore be inferred from category economics.
| Financial period | Expected market condition | LEVORA implication |
|---|---|---|
| Launch and early commercialization | Limited competition relative to the current market | Higher potential pricing and manufacturer retention |
| Mature branded/generic transition | Entry of competing products | Rapid erosion in price and share |
| Current mature-generic phase | Multiple equivalent products and payer control | Low unit economics and volume-dependent returns |
| Discontinuation or reduced distribution | Manufacturer rationalization | Revenue declines even if category demand remains stable |
| Replacement by equivalent NDCs | Pharmacy substitution | Product-level sales migrate to other manufacturers |
The most likely financial path is a sharp decline from any earlier branded economics, followed by a low-margin maintenance phase. Revenue depends on retaining pharmacy listings and securing supply contracts rather than on patent-protected pricing.
For a manufacturer, LEVORA can remain economically rational if:
- Manufacturing cost is low.
- The product is included in high-volume payer formularies.
- Production runs are efficient.
- Regulatory and pharmacovigilance costs remain limited.
- The manufacturer can bundle the product with a broader contraceptive portfolio.
The product becomes less attractive if demand is fragmented across many NDCs, reimbursement falls below sustainable levels, or the manufacturer faces recurring supply or compliance costs.
What generic entry risks exist for LEVORA?
Generic entry risk is high because the product is already in a mature generic environment.
The main entry risks are commercial rather than legal:
- Price undercutting by additional ANDA holders.
- Preferred-formulary displacement.
- Pharmacy substitution away from the LEVORA NDC.
- Manufacturing disruption.
- Product discontinuation by the current sponsor.
- Contract loss to private-label suppliers.
- Patient migration to long-acting contraceptives or alternative oral formulations.
A new entrant would face low patent risk but high market-access risk. FDA approval alone would not guarantee meaningful sales. The entrant would need competitive pricing, stable supply, wholesaler access, and payer acceptance.
Which companies are challenging LEVORA?
No major patent challenger is required to enter the core market because LEVORA’s formulation is exposed to established generic competition. Competition comes from manufacturers and marketers of equivalent levonorgestrel/ethinyl estradiol products rather than from litigants seeking to invalidate a blocking patent.
The competitive field includes companies associated with generic oral contraceptive supply, including:
- Perrigo and affiliated contraceptive businesses.
- Mayne Pharma.
- Glenmark Pharmaceuticals.
- Lupin.
- Teva Pharmaceuticals.
- Amneal Pharmaceuticals.
- Xiromed and other generic marketers.
- Private-label and contract-manufacturing suppliers.
Participation varies by product, NDC, strength, dosage regimen, and marketing period. Company-level competition should be verified against current FDA listings and commercial product databases rather than inferred solely from historical brand names.
What patent litigation affects LEVORA?
No material patent litigation is identified as a central commercial issue for LEVORA 0.15/30-21.
The low litigation exposure reflects:
- Expired active-ingredient patents.
- A simple conventional tablet formulation.
- No evident device or delivery-system claim.
- No meaningful biosimilar pathway.
- No high-value method-of-use exclusivity.
- Numerous existing equivalent products.
Potential disputes would more likely involve trademark use, product labeling, manufacturing quality, distribution agreements, reimbursement, or a product-specific regulatory action.
Does LEVORA have biosimilar risk?
Biosimilar risk does not apply to LEVORA.
LEVORA is a small-molecule oral tablet, not a biologic. Competition proceeds through abbreviated new drug applications and therapeutic equivalence, not through the biosimilar pathway under the Public Health Service Act.
The relevant competitive risk is generic substitution. FDA therapeutic-equivalence determinations and state pharmacy-substitution rules are more important than biosimilar interchangeability standards. [2]
How does LEVORA compare with newer contraceptives?
| Factor | LEVORA | Newer contraceptive products |
|---|---|---|
| Active ingredients | Levonorgestrel and ethinyl estradiol | May use different estrogen or progestin |
| Delivery | Daily oral tablet | Oral, implant, IUD, ring, patch, injection |
| Patent position | Minimal or expired protection | Some products retain formulation or device patents |
| Price | Generally low generic pricing | Often higher, especially for devices |
| Adherence | Daily use required | Long-acting products reduce daily adherence burden |
| Market access | Broad pharmacy distribution | May require specialty, clinic, or device channels |
| Differentiation | Limited | May include dosing, bleeding, tolerability, or convenience claims |
LEVORA remains competitive on cost and familiarity. It is weaker on adherence convenience and product differentiation than long-acting reversible contraceptives.
What geographic coverage does LEVORA have?
The primary commercial relevance is the U.S. market. U.S. coverage depends on FDA approval, NDC maintenance, state substitution rules, and payer formularies.
International markets may contain equivalent levonorgestrel/ethinyl estradiol products under different brand names and regulatory classifications. A U.S. LEVORA product does not automatically provide international regulatory or trademark coverage.
Geographic expansion would require:
- Country-specific marketing authorization.
- Local labeling and pharmacovigilance.
- Pricing and reimbursement approval.
- Importation and supply-chain compliance.
- Trademark clearance.
- Local distribution arrangements.
For a mature oral contraceptive, international growth is more likely to come from portfolio distribution than from a proprietary LEVORA patent strategy.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate operationally but low from a patent perspective.
The product requires validated production of low-dose hormonal tablets, content-uniformity controls, dissolution testing, stability data, packaging controls, and compliance with current good manufacturing practices. Hormonal products also require strict handling and contamination controls.
The primary barriers are:
- FDA-compliant tablet manufacturing.
- Reliable supply of active ingredients.
- Quality systems and batch release.
- Regulatory maintenance.
- Commercial scale.
- Payer and wholesaler access.
These barriers can limit the number of successful commercial suppliers, but they do not create durable exclusivity comparable to a patented delivery system or biologic manufacturing process.
Key Takeaways
- LEVORA 0.15/30-21 contains levonorgestrel 0.15 mg and ethinyl estradiol 0.03 mg.
- The product is in a mature generic contraceptive market.
- No material patent estate or biosimilar protection supports the product.
- Paragraph IV litigation risk is low relative to branded products with active patents.
- Competition comes from numerous equivalent oral contraceptives and alternative contraceptive methods.
- Product-level revenue is not separately disclosed in public company filings.
- The financial trajectory is likely characterized by long-term price erosion, low margins, and dependence on manufacturing reliability and payer access.
- The main commercial risk is product displacement or discontinuation, not patent expiry.
- LEVORA’s competitive strengths are low cost, established use, and broad pharmacy familiarity.
- Its weaknesses are limited differentiation, daily adherence requirements, and exposure to formulary substitution.
FAQs About LEVORA 0.15/30-21
Is LEVORA 0.15/30-21 still being manufactured?
Manufacturing status depends on the specific NDC and sponsor. Some LEVORA-branded listings may be discontinued or replaced, while equivalent levonorgestrel/ethinyl estradiol products remain widely available.
Is LEVORA the same as Portia-28?
LEVORA and Portia-28 use the same active-ingredient strengths, but packaging, manufacturer, inactive ingredients, NDC, and tablet count may differ. A pharmacist or prescriber determines whether a substitution is appropriate under the applicable prescription and state law.
Can a generic company launch LEVORA without a patent license?
Generally, yes, if the applicant satisfies FDA requirements and does not infringe an applicable unexpired patent. The core active ingredients and conventional tablet combination do not present a significant remaining patent barrier.
Why might a pharmacy substitute another contraceptive for LEVORA?
Pharmacies may substitute an equivalent product because of payer formulary rules, wholesaler availability, manufacturer supply, reimbursement, or state substitution law. The substitute may have a different brand name or package configuration while containing the same active ingredients.
Is LEVORA affected by the FDA approval of over-the-counter birth-control pills?
The approval of Opill expands contraceptive access through a different progestin-only product. It does not convert LEVORA into an over-the-counter product or remove LEVORA’s prescription status. [3]
References
-
U.S. Food and Drug Administration. (n.d.). Label: Levonorgestrel and ethinyl estradiol tablets. DailyMed.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
-
U.S. Food and Drug Administration. (2023, July 13). FDA approves first nonprescription daily oral contraceptive. https://www.fda.gov
-
U.S. Department of Health and Human Services. (n.d.). Affordable Care Act implementation: Women’s preventive services. HealthCare.gov.
More… ↓

